T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype - Top-Institutions - MDSpire

T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Miami, Sylvester Comprehensive Cancer Center
    University of Miami, Sylvester Comprehensive Cancer Center

    Miami, Florida

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    University of Pennsylvania, Abramson Cancer Center
    University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Helsinki University Hospital
    Helsinki University Hospital

    Helsinki, Finland

    Key Differentiators

    • Hematology

  • #4

    Hematology and Hemotherapy Center of the University of Campinas
    Hematology and Hemotherapy Center of the University of Campinas

    Campinas, São Paulo

    Key Differentiators

    • Hematology

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype

  • by Aaron B. Schultz, Molly Dalzell, Luis Nivelo, Sarah E. Henrickson, Alejandro V. Villarino

  • May 5, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...